Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.

ABSTRACT: Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. With its overall dismal prognosis (the median survival is 14 months), GBMs demonstrate a resounding resilience against all current treatment modalities. The absence of a major progress in the treatment of GBM maybe a result of our poor understanding of both GBM tumor biology and the mechanisms underlying the acquirement of treatment resistance in recurrent GBMs. A comprehensive understanding of these markers is mandatory for the development of treatments against therapy-resistant GBMs. This review also provides an overview of a novel marker called acid ceramidase and its implication in the development of radioresistant GBMs. Multiple signaling pathways were found altered in radioresistant GBMs. Giv

SUBMITTER: Nguyen HS 

PROVIDER: S-EPMC6032212 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature